Seperation and synthesis of the compound "hiponol" with hypoglycemic activity from seaweed by Institute of Oceanography, Chinese Academy of Sciences

Recently, Shi Dayong, a researcher at the center for research and development of marine biotechnology, Institute of Oceanography, Chinese Academy of Sciences, has successfully obtained the US patent authorization for the compound "hyponol", which was first isolated and synthesized from the active ingredients of seaweeds in the world As a kind of marine drug, the compound has good hypoglycemic effect and can be widely used in the treatment of type 2 diabetes and obesity At present, the Institute of Oceanography of the Chinese Academy of Sciences has signed an intention cooperation with enterprises, and will do enough "homework" in preclinical research to input "fresh blood" for the pharmaceutical industry In the current domestic pharmaceutical market, generic drugs account for 97% of the ultra-high share, and the industrialization of innovative drugs is a long and slow way For enterprises, the risk of developing innovative drugs is much higher than the production of generic drugs However, compared with low margin generic drugs, any "popular" drugs will make considerable profits if they can go to the market Therefore, as a candidate drug for diabetes treatment, once it enters the market, it will not only bring considerable economic benefits to the enterprise, but also become a sample for the development of marine drugs, providing a new support for the development of biomedical industry After a long period of experimental research, the team of Shi Dayong, who has been studying the active ingredients in seaweeds, has finally found "hiponol" with hypoglycemic activity in nearly a thousand compounds "Due to the low yield of seaweed and the low content of the active substance in natural seaweed, only tens of milligrams can be extracted as the basic raw material for each experiment, which not only prolongs the experiment cycle, but also wastes human and material resources." Shi Dayong, a researcher at the center for research and development of marine biotechnology, Institute of Oceanography, Chinese Academy of Sciences, told reporters, "we can solve the problem of" less amount and less dilution "by chemical means We can synthesize 100 grams of compounds each time, and get rid of the restriction of low content of active ingredients in seaweeds." When scientists found that this compound in seaweed has hypoglycemic activity, a long-term battle for new drug development is about to start "The experiment shows that after administration by gavage," hiponol "has successfully reduced the amount of food taken by mice, prevented weight gain, and significantly reduced their blood glucose and glycosylated hemoglobin, which is the long-term control index of blood glucose, which is equivalent to the hypoglycemic effect of the positive control drug" rosiglitazone " "At present, hiponol is comparing with metformin and rosiglitazone, two popular hypoglycemic drugs on the market, in terms of efficacy and safety, and the latest test results are expected to be obtained in February," said Shi The new drug market cycle is complex and long If the experimental results prove that all the properties of "hiponol" are "up to standard", then it will enter the preclinical research, and the expected cycle is 3-5 years "Generally speaking, the listing of new drugs requires 3-5 years of preclinical research, and phase I, phase II and phase III clinical trials after obtaining clinical approval After being approved by the State Drug and food administration, new drug certificates are obtained for production and listing This process will take about ten years " "In the biomedical industry in the United States, there is a" double decade "saying that it takes" ten years "and" one billion dollars "for a new drug to go on the market," Shi told reporters Of course, not every new drug needs to be listed in the "double ten" to pave the way, but it is not easy for an innovative drug to enter the market "For drugs, safety is the first thing On the premise of similar hypoglycemic effect, how to make the human body absorb better, take in smaller amount of drugs, and improve the safety of drugs is the problem we will focus on and solve in the next step." "At present, many insulin antidiabetic drugs in the market are given by injection, and we hope to take orally as the main form, which is more convenient for patients," said Shi Shi Dayong, a researcher at the center for research and development of marine biotechnology, Institute of Oceanography, Chinese Academy of Sciences, is doing experimental "innovation" to bring light to the pharmaceutical industry At present, 97% of the domestic pharmaceutical market is generics, and the proportion of innovative drugs is very small It is reported that generic drugs refer to the substitute drugs imitated by pharmaceutical companies that do not own the patent after the end of the patent protection period As Chinese pharmaceutical companies are unable to independently develop chemicals, generic drugs have become a lifesaver for many domestic pharmaceutical companies Some experts pointed out that the purpose of China's imitated testing standards is not to "reflect the quality of drugs", but "to make drugs qualified" This kind of standard of "looking at the face" without looking at the curative effect is just like chasing the end, which makes Chinese pharmaceutical enterprises fall into a vicious circle of "low standard - less investment in research and development - only copying foreign drugs" For enterprises, the investment cost and risk of generic drugs are far less than that of innovative drugs Therefore, a large number of pharmaceutical enterprises choose generic drugs as a "good recipe" for their survival But for the common people, the price gap of the expensive imported drugs after changing into generic drugs makes more and more people begin to accept the existence of generic drugs On the one hand, it is better than the enterprise, on the other hand, the common people pay the bill, which is also the reason why the generic drug market is growing "For researchers, we still hope to have more innovative drugs To provide more "voice" for the development of China's biomedical industry " "The discovery of hipono is just the first step in the Long March," Shi told reporters Now it can only be said that in the future, it may become an innovative medicine to enter people's lives, but in this process, we and enterprises will face great challenges, and there is a long way to go in the future " Link: new marine drugs "broaden" the pharmaceutical industry pattern, "marine drug product - 'fucoidan sulfate' achieved an output value of 500 million yuan in 2014." This news makes people begin to pay attention to a series of industrial changes brought about by new marine drugs The development of new marine drugs has never stopped in recent years For example, "mannitol nicotinic acid tablet" made of mannitol and nicotinic acid contained in kelp has the function of lowering blood fat and clarifying blood; the "mother of Pearl injection" made from the reproductive nest of pearl oyster, Hepu, has a total effective rate of 75% in the treatment of viral hepatitis, and the "sea star gum instead of plasma" developed by starfish has a good colloidal osmotic pressure, which can effectively expand blood volume and promote the body Tissue recovery There are also a series of products for the development of marine medicinal resources, such as "Pearl tablet", "Pearl Capsule" and "pearl film agent" The development of new marine drugs has undoubtedly brought a "spring breeze" to the development of biomedical industry, not only providing a broader development direction for the industry, but also opening up a new profit market for enterprises.